BeStock  
Stocks › Biotechnology › SYRE

Spyre Therapeutics SYRE

US equityMarket cap rank #1512Biotechnology
$93.47 −$4.16 (-4.26%)
Market closed · Nov 22, 5:50 am ET · Last extended-hours $93.47 0.00%
Open$95.93
Prev close$97.63
Day range$93.22 – $99.56
Volume805.4K
Market cap$8.88B
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$0.00
Operating profit-$105.72M-85.8% YoY
Net profit-$96.12M-759.5% YoY
Diluted EPS-$0.94-526.7% YoY
Free cash flow-$77.50M-108.8% YoY
Operating cash flow-$77.50M

Revenue, last 8 quarters

$0.0Dec '24$0.0Mar '25$0.0Jun '25$0.0Sep '25$0.0Dec '25$0.0Mar '26$0.0Jun '26$0.0Sep '26

Net profit, last 8 quarters

$-56.3MDec '24$-44.8MMar '25$-36.7MJun '25$-11.2MSep '25$-62.5MDec '25$-69.0MMar '26$-36.2MJun '26$-96.1MSep '26

Diluted EPS by quarter

-0.81Dec '24-0.60Mar '25-0.60Jun '25-0.15Sep '25-0.70Dec '25-0.74Mar '26-0.43Jun '26-0.94Sep '26

Free cash flow by quarter

$-37.2MDec '24$-41.0MMar '25$-46.6MJun '25$-37.1MSep '25$-44.6MDec '25$-57.4MMar '26$-69.9MJun '26$-77.5MSep '26

Annual revenue

$0.0FY20$18.7MFY21$2.3MFY22$886.0KFY23$0.0FY24$0.0FY25

Profitability & balance sheet

Return on equity-42.0%
Return on assets-31.5%
Return on invested capital-47.7%
Current ratio27.40
Liabilities / assets4.4%
Cash & investments$1.07B
Net cash (debt)$1.07B

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Operating Revenue $0.00 $0.00 $0.00 $0.00 $0.00
Operating Expense $105.72M $81.64M $75.64M $219.56M $57.17M
Selling and Admin Expenses $16.55M $16.14M $15.23M $47.91M $12.53M
-General & Admin Expense $16.55M $16.14M $15.23M $47.91M $12.53M
Research & Development $89.17M $65.50M $60.41M $171.65M $44.64M
Operating Profit -$105.72M -$81.64M -$75.64M -$219.56M -$57.17M
Net Non-Operating Interest Income (Expense) $10.63M $10.05M $7.00M $24.89M $7.14M
Non-Operating Interest Income $10.63M $10.05M $7.00M $24.89M $7.14M
Other Income (Expense) -$1.03M $35.39M -$359,000.00 $39.46M -$12.50M
Special Income (Charges) $0.00 $40.00M $30.00M $10.00M $0.00
-Gain on Sale of Property/Plant/Equipment $0.00 $40.00M $30.00M $10.00M $0.00
Other Non-Operating Income (Expenses) -$1.03M -$4.61M -$30.36M $29.46M -$12.50M
Pretax Profit -$96.12M -$36.20M -$69.01M -$155.22M -$62.53M
Tax $0.00 $0.00 $0.00 -$15,000.00 $0.00
Net Profit -$96.12M -$36.20M -$69.01M -$155.20M -$62.53M
Profit from Continuing Operations -$96.12M -$36.20M -$69.01M -$155.20M -$62.53M
Net Income to Parent Company -$96.12M -$36.20M -$69.01M -$155.20M -$62.53M
Preferred Stock Dividends -$13.01M – – – –
Net Income to Common Stockholders -$83.11M -$36.20M -$69.01M -$155.20M -$80.49M
Basic EPS -$0.94 -$0.43 -$0.74 -$1.98 -$0.70
Diluted EPS -$0.94 -$0.43 -$0.74 -$1.98 -$0.70
Total Revenue as Reported – – – $0.00 –

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $1.10B $1.17B $763.95M $777.78M $777.78M
Total Current Assets $1.10B $1.17B $763.95M $777.78M $777.78M
Cash and Cash Equivalents & Short-Term Investments $1.07B $1.15B $741.47M $756.53M $756.53M
-Cash and Cash Equivalents $82.73M $162.01M $97.19M $85.72M $85.72M
-Short Term Investments $989.18M $983.34M $644.28M $670.81M $670.81M
Other Current Assets $27.82M $27.66M $22.49M $21.25M $21.25M
Total Non-Current Assets $0.00 $0.00 $0.00 $0.00 $0.00
Total Liabilities $48.19M $71.86M $93.14M $62.55M $62.55M
Total Current Liabilities $40.14M $63.30M $85.16M $58.69M $58.69M
Payables $9.55M $5.77M $5.74M $8.92M $8.92M
-Accounts Payable $9.47M $5.72M $5.69M $8.90M $8.90M
-Due to Related Parties Current $82,000.00 $46,000.00 $50,000.00 $14,000.00 $14,000.00
Current Accrued Expenses $23.25M $20.46M $24.09M $18.83M $18.83M
Total Non-Current Liabilities $8.05M $8.56M $7.98M $3.86M $3.86M
Other Non-Current Liabilities $8.05M $8.56M $7.98M $3.86M $3.86M
Total Equity $1.05B $1.10B $670.81M $715.24M $715.24M
Stockholders' Equity $1.05B $1.10B $670.81M $715.24M $715.24M
Capital Stock $146.44M $146.44M $155.84M $155.84M $155.84M
-Common Stock $16,000.00 $16,000.00 $15,000.00 $15,000.00 $15,000.00
-Preferred Stock $146.43M $146.43M $155.82M $155.82M $155.82M
Additional Paid-In Capital $2.24B $2.19B $1.71B $1.69B $1.69B
Retained Earnings -$1.33B -$1.23B -$1.20B -$1.13B -$1.13B
Gains/Losses Not Affecting Retained Earnings -$5.38M -$2.40M -$767,000.00 $869,000.00 $869,000.00
Other Current Liabilities – $31.35M $50.26M $23.00M $23.00M

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow -$77.50M -$69.88M -$57.37M -$169.25M -$44.58M
Net cash flow from continuing operations -$77.50M -$69.88M -$57.37M -$169.25M -$44.58M
Net Income from Continuing Operations -$96.12M -$36.20M -$69.01M -$155.20M -$62.53M
Gain/Loss from Continuing Operations $0.00 -$40.00M -$30.00M -$10.00M $0.00
Other Non-Cash Items $257,000.00 $5.29M $30.27M -$29.77M $12.43M
Change in Working Capital $8.54M -$9.01M $244,000.00 -$5.93M -$2.27M
-Change in Prepaid Assets $51,000.00 -$5.61M -$233,000.00 -$12.82M -$2.88M
-Change in Payables and Accrued Expense $8.49M -$3.40M $477,000.00 $6.89M $615,000.00
Net cash flow from investing -$3.80M -$297.90M $56.58M -$143.48M -$247.41M
Net Cash Flow from Continuing Investing Activities -$3.80M -$297.90M $56.58M -$143.48M -$247.41M
Net Intangibles Purchase and Sale $0.00 $40.00M $30.00M $7.00M $0.00
Net Investment Purchase and Sale -$3.80M -$337.90M $26.58M -$150.48M -$247.41M
Financing Cash Flow $2.02M $432.60M $12.26M $309.03M $312.81M
Net Cash Flow from Continuing Financing Activities $2.02M $432.60M $12.26M $309.03M $312.81M
Net Common Stock Issuance $29.53M $435.24M $9.75M $311.13M $311.13M
Proceeds from Stock Option Exercised $5.59M $20.58M $2.68M $3.31M $1.75M
Net Other Financing Charges -$33.10M -$23.22M -$171,000.00 -$5.41M -$69,000.00
Ending Cash Balance $82.73M $162.01M $97.19M $85.72M $85.72M
Net Change in Cash -$79.28M $64.82M $11.46M -$3.70M $20.82M
Beginning Cash Balance $162.01M $97.19M $85.72M $89.42M $64.90M
Free Cash Flow -$77.50M -$69.88M -$57.37M -$169.25M -$44.58M
Depreciation & Depletion & Amortization – – – $0.00 –
-Change in Receivables – – – $0.00 –
-Change in Other Current Liabilities – – – $0.00 –
Net PPE Purchase and Sale – – – $0.00 –
Net Business Purchase and Sale – – – $0.00 –
Net Preferred Stock Issuance – – – $0.00 $0.00
Effect of Exchange Rate Changes – – – $0.00 $0.00

Discussion

No comments yet — be the first to weigh in on SYRE.

Sign in to join the discussion.

Scroll to Top